Survival outcomes in patients who progressed after CD19 CAR T-cell therapy. (A) EFS of patients who achieved CR to salvage treatments for post-CAR T disease progression. Median EFS was 4.5 months (2.1-32.1 months). (B) OS from post–CAR T progression of 38 patients who progressed after CD19 CAR T-cell therapy. Median OS was 7.5 months (95% CI, 4.2-13.9 months) with corresponding 1-year OS of 35% (95% CI, 23-56).